Weight Regain After Stopping GLP-1 Drugs Gets a Pooled Analysis

What the new weight regain after stopping GLP-1 analysis covers

The paper, authored by Qi, Gao, Chen and colleagues and published in the open-access journal PeerJ, is indexed as a systematic review and meta-analysis. Its stated scope is weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese. In plain terms, the authors set out to gather the published studies that followed people after treatment stopped and to combine those results statistically.

That framing matters because it inverts the usual question. Most of the large trials in this class — the ones that made semaglutide and tirzepatide household names — were designed to measure what happens while people are on treatment. The discontinuation literature is smaller, more scattered, and has mostly been read one study at a time. A meta-analysis is an attempt to read it all at once.

PeptideWiz has not reproduced the pooled effect sizes here because the abstract record available at publication does not carry them, and reporting a number we cannot verify would be worse than reporting none. Readers who want the magnitude estimates should go to the paper itself, which is open access.

Why discontinuation is a separate research question

GLP-1 receptor agonists mimic a gut hormone that slows gastric emptying and acts on appetite signalling in the brain. Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for weight management, is the best-known single-receptor version. Tirzepatide, sold as Mounjaro and Zepbound, adds activity at the GIP receptor and is described as a dual agonist. Both are given as weekly subcutaneous injections.

The prevailing clinical framing is that obesity is a chronic condition and that these drugs treat it for as long as they are taken. That framing predicts regain after withdrawal, and prior trial extensions in which participants were taken off treatment have reported exactly that pattern. What has been less settled is how much, how fast, and whether it differs by drug, by starting weight, or by how long someone was treated.

Discontinuation is not hypothetical for this audience. People stop because insurance coverage lapses, because a compounded source becomes unavailable after a shortage is resolved, because of tolerability, or because they and their prescriber agreed on a defined course. Each of those exits looks different, and a pooled analysis is the first step toward telling them apart.

If your protocol involves semaglutide, the semaglutide dosage calculator can help you keep your own records consistent between refills and supply changes.

The PeerJ systematic review and meta-analysis by Qi, Gao, Chen and colleagues examines weight regain following discontinuation of GLP-1 receptor agonists in adults who are overweight or obese. the PeerJ systematic review and meta-analysis.

What a systematic review and meta-analysis can and cannot establish

A systematic review follows a pre-specified search protocol to find every study meeting defined criteria, rather than selecting the convenient ones. A meta-analysis then combines their results into a single pooled estimate. The method's strength is that it reduces the influence of any one small study. Its weakness is that the pooled figure is only as good as the studies feeding it.

Two limitations recur in this particular literature. Follow-up periods vary widely, so a pooled average may blend six-month and two-year observations. And the underlying studies mix randomized withdrawal designs with observational follow-up of people who stopped for their own reasons — groups that are not comparable, because the reason someone stops is itself linked to how they fare afterward.

None of that makes the exercise unhelpful. It means the pooled number is a summary of the current evidence rather than a prediction about any individual, and it should be read as an argument about the shape of the problem rather than a personal forecast.

The same applies on the dual-agonist side, where the tirzepatide dosage calculator handles the arithmetic your log depends on.

Beaudart, Malréchauffé, van Heden and co-authors published a pooled analysis of musculoskeletal outcomes in Drugs covering muscle and bone in people treated with GLP-1 receptor agonists.

Muscle and bone: the parallel evidence published alongside it

Appearing in the same window of new indexing is a systematic literature review and meta-analysis by Beaudart, Malréchauffé, van Heden and colleagues in the journal Drugs, examining GLP-1 receptor agonists and musculoskeletal outcomes. Musculoskeletal here means skeletal muscle and bone — the tissues that come along for the ride during rapid weight loss and that do not necessarily rebuild when weight returns.

Alongside it, Kim and Kim published a review in Diabetes & Metabolism Journal framing sarcopenia as the outstanding challenge of incretin-based therapy. Sarcopenia is the age- or illness-related loss of muscle mass and function; the concern in this context is that weight lost on these drugs is not purely fat, and that the lean tissue component may not be regained proportionally if weight comes back.

Read together, the three papers describe one composite question rather than three separate ones. If weight returns after discontinuation but body composition does not return to its starting point, then the relevant outcome is not the number on a scale. That is a materially different way of evaluating a course of treatment, and it is the direction the research literature appears to be moving.

Distinguishing a supply gap from a deliberate stop is the core of useful adherence tracking, and it is the detail most often lost after the fact.

Kim and Kim contributed a review of incretin-related sarcopenia in Diabetes & Metabolism Journal, framing muscle loss as an outstanding challenge of these therapies.

What remains unresolved

The big open question is prediction: who regains most, and can that be identified in advance. Candidate factors include treatment duration, the degree of loss achieved, whether structured nutrition and resistance training accompanied treatment, and whether the stop was abrupt or managed. None of the papers in this batch claims to have settled that, and the discontinuation meta-analysis is explicitly a synthesis of what already exists.

Also unresolved is whether the dual agonists behave differently from the single-receptor drugs on withdrawal. Head-to-head randomized withdrawal comparisons between tirzepatide and semaglutide are not what these reviews report, so any claim that one holds weight better after stopping is, for now, an extrapolation rather than a finding.

The surrounding literature indexed the same week shows how wide the field has become: an international expert panel update in Gut on resmetirom and semaglutide in MASH-related fibrosis, a multicenter retrospective cohort in the Journal of Asthma and Allergy comparing tirzepatide and semaglutide on asthma exacerbation risk, and propensity-matched work in Intestinal Research on inflammatory bowel disease. The class is being studied well beyond glycemic control and weight.

If the vocabulary around planned courses and interruptions is unfamiliar, our glossary entry on what a protocol is sets out the terms.